SynthesisBMC medicine2017
Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis.
Synthesis in BMC medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 6 syntheses or guidelines pooled it, 104 citations in OpenAlex.
- Atypical Signs and Symptoms of Giant Cell Arteritis: A Systematic Review.Journal of general internal medicine · 2025Pooled it
- Diagnostic delay in adult inflammatory bowel disease: A systematic review.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2023Pooled it
- Diagnostic Delay in Pediatric Inflammatory Bowel Disease: A Systematic Review.Digestive diseases and sciences · 2022Pooled it
- Pooled it
- Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis.JAMA internal medicine · 2020Pooled it
- European Headache Federation recommendations for neurologists managing giant cell arteritis.The journal of headache and pain · 2020Pooled it
- FDG-PET/CT useful for rapid diagnosis of large-vessel giant cell arteritis.Internal and emergency medicine · 2026Article
- Time to diagnosis in large vessel vasculitis: insights from a retrospective study at a tertiary rheumatology centre.RMD open · 2026Article
- Orofacial symptoms and diagnostic pathways in patients with giant cell arteritis (GCA): a retrospective case series from a dental perspective.BMC oral health · 2026Article
- Cranial and Systemic Manifestations of Giant Cell Arteritis: Two Sides of the Same Coin.Cureus · 2026Article
- The characteristics of giant cell arteritis patients that went blind in spite of treatment: case based narrative literature review.Rheumatology international · 2026Review
- Barriers to immediate corticosteroid treatment in suspected giant cell arteritis with visual symptoms: insights from a tertiary eye care unit.BMC ophthalmology · 2026Article
- Understanding the patient experience of newly diagnosed giant cell arteritis.Rheumatology advances in practice · 2026Article
- Rurality and Delayed Diagnosis of Giant Cell Arteritis-A Single-Center Experience.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases · 2025Article
- Article
- Real-World Analysis of Patient Characteristics, Adverse Events, and Economic Burden Among Patients with Giant Cell Arteritis Treated with Glucocorticoids.Rheumatology and therapy · 2025Article
- Illness Burden and Unmet Patient Needs in Giant Cell Arteritis: Current State and Future Prospects.Open access rheumatology : research and reviews · 2025Review
- The role of calprotectin in giant cell arteritis - from pathophysiology to possible clinical applications.Frontiers in immunology · 2025Review
- Diagnostic Dilemmas in Giant Cell Arteritis: Overcoming Anchoring Bias.Case reports in rheumatology · 2025Article
- Cranial and extracranial manifestations of giant cell arteritis: a single-center observational study.Rheumatology international · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundGiant cell arteritis (GCA), if untreated, can lead to blindness and stroke. The study's objectives were to (1) determine a new evidence-based benchmark of the extent of diagnostic delay for GCA and (2) examine the role of GCA-specific characteristics on diagnostic delay.
methodsMedical literature databases were searched from inception to November 2015. Articles were included if reporting a time-period of diagnostic delay between onset of GCA symptoms and diagnosis. Two reviewers assessed the quality of the final articles and extracted data from these. Random-effects meta-analysis was used to pool the mean time-period (95% confidence interval (CI)) between GCA symptom onset and diagnosis, and the delay observed for GCA-specific characteristics. Heterogeneity was assessed by I
resultsOf 4128 articles initially identified, 16 provided data for meta-analysis. Mean diagnostic delay was 9.0 weeks (95% CI, 6.5 to 11.4) between symptom onset and GCA diagnosis (I
conclusionsThe mean delay from symptom onset to GCA diagnosis was 9 weeks, or longer when cranial symptoms were absent. Our research provides an evidence-based benchmark for diagnostic delay of GCA and supports the need for improved public awareness and fast-track diagnostic pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.